A protocol was drawn up and a prospective randomized study was carried out to test the effectiveness of BCG on lung cancer. BCG obtained from the Japan BCG Institute was used. A dose of 5.4 mg or 2−4 × 108 viable organisms was administered into the arm by the tine technique. Administration of BCG was carried out once before surgery and four times after surgery. Surgery consisted basically of radical lobectomy or pneumonectomy with complete mediastinal lymphadenectomy.
The survival rate in the BCG administered group was significantly (P < 0.05) more than in the control group. Further, when only the cases that were treated strictly in accordance with the protocol were taken into consideration, the effectiveness of BCG was even more significant (P < 0.02). The period of observation of these cases was from a minimum of 10 months to a maximum of 28 months.
On the basis of these results, it can be said that BCG is beneficial in the treatment of lung cancer.